SEC Form 4 · accession 0001209191-18-056052

PhaseBio Pharmaceuticals Inc · PHAS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Linda Tufts

Director

Period of report

Oct 22, 2018

Accepted (ET)

Oct 24, 2018 · 4:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001169245

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Oct 22, 2018	C	577,486	—	A	577,486	I	By Fletcher Spaght Ventures II, LP
Common Stock^F2	Oct 22, 2018	P	12,682	$5.00	A	590,168	I	By Fletcher Spaght Ventures II, LP
Common Stock^F1,F2	Oct 22, 2018	C	58,152	—	A	58,152	I	By FSV II, LP
Common Stock^F2	Oct 22, 2018	P	1,277	$5.00	A	59,429	I	By FSV II, LP
Common Stock^F1,F2	Oct 22, 2018	C	275,055	—	A	275,055	I	By FSV II-B, LP
Common Stock^F2	Oct 22, 2018	P	6,041	$5.00	A	281,096	I	By FSV II-B, LP

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrants to Purchase Series B Preferred Stock^F2,F4,F1	$0.12	Oct 22, 2018	M	7,053	D	—	—	Series B Preferred Stock	7,053	0	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	M	7,053	A	—	—	Common Stock	7,053	347,420	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	S	170	D	—	—	Common Stock	170	347,250	I
Warrants to Purchase Series B Preferred Stock^F2,F4,F1	$0.12	Oct 22, 2018	M	710	D	—	—	Series B Preferred Stock	710	0	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	M	710	A	—	—	Common Stock	710	34,986	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	S	18	D	—	—	Common Stock	18	34,968	I
Warrants to Purchase Series B Preferred Stock^F2,F4,F1	$0.12	Oct 22, 2018	M	3,359	D	—	—	Series B Preferred Stock	3,359	0	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	M	3,359	A	—	—	Common Stock	3,359	165,476	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	S	81	D	—	—	Common Stock	81	165,395	I
Warrants to Purchase Series C-1 Preferred Stock^F2,F4,F1	$0.12	Oct 22, 2018	M	9,847	D	—	—	Series C-1 Preferred Stock	9,847	0	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	M	9,847	A	—	—	Common Stock	9,847	47,377	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	S	237	D	—	—	Common Stock	237	47,140	I
Warrants to Purchase Series C-1 Preferred Stock^F2,F4,F1	$0.12	Oct 22, 2018	M	991	D	—	—	Series C-1 Preferred Stock	991	0	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	M	991	A	—	—	Common Stock	991	4,770	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	S	24	D	—	—	Common Stock	24	4,746	I
Warrants to Purchase Series C-1 Preferred Stock^F2,F4,F1	$0.12	Oct 22, 2018	M	4,690	D	—	—	Series C-1 Preferred Stock	4,690	0	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	M	4,690	A	—	—	Common Stock	4,690	22,565	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	S	113	D	—	—	Common Stock	113	22,452	I
Series AA Preferred Stock^F2,F1	—	Oct 22, 2018	C	119,408	D	—	—	Common Stock	119,408	0	I
Series AA Preferred Stock^F2,F1	—	Oct 22, 2018	C	12,025	D	—	—	Common Stock	12,025	0	I
Series AA Preferred Stock^F2,F1	—	Oct 22, 2018	C	56,874	D	—	—	Common Stock	56,874	0	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	C	347,250	D	—	—	Common Stock	347,250	0	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	C	34,968	D	—	—	Common Stock	34,968	0	I
Series B Preferred Stock^F2,F1	—	Oct 22, 2018	C	165,395	D	—	—	Common Stock	165,395	0	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	C	47,140	D	—	—	Common Stock	47,140	0	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	C	4,746	D	—	—	Common Stock	4,746	0	I
Series C-1 Preferred Stock^F2,F1	—	Oct 22, 2018	C	22,452	D	—	—	Common Stock	22,452	0	I
Series D Preferred Stock^F2,F1	—	Oct 22, 2018	C	63,688	D	—	—	Common Stock	63,688	0	I
Series D Preferred Stock^F2,F1	—	Oct 22, 2018	C	6,413	D	—	—	Common Stock	6,413	0	I
Series D Preferred Stock^F2,F1	—	Oct 22, 2018	C	30,334	D	—	—	Common Stock	30,334	0	I

Explanation of responses

F1Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
F2FSA II, LLC is the general partner of the general partner of Fletcher Spaght Ventures II, LP and FSV II-B, LP and the manager of the general partner of FSV II, LP. The reporting person is a managing member of FSA II, LLC and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
F4The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.